Illumina, Inc. (NASDAQ:ILMN) Receives Average Rating of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned an average rating of “Hold” from the nineteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $332.24.

A number of equities research analysts have recently weighed in on ILMN shares. Wells Fargo & Co raised their price objective on shares of Illumina from $245.00 to $290.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Piper Sandler reduced their price objective on shares of Illumina from $370.00 to $356.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Cowen raised their price objective on shares of Illumina from $275.00 to $320.00 and gave the company an “outperform” rating in a report on Friday, May 1st. Citigroup lowered shares of Illumina from a “buy” rating to a “neutral” rating and raised their price objective for the company from $250.00 to $320.00 in a report on Friday, April 24th. They noted that the move was a valuation call. Finally, Stifel Nicolaus raised their price objective on shares of Illumina from $298.00 to $325.00 and gave the company a “buy” rating in a report on Friday, May 1st.

ILMN stock traded down $6.17 during midday trading on Friday, hitting $360.08. The company’s stock had a trading volume of 868,230 shares, compared to its average volume of 899,668. The company has a quick ratio of 3.74, a current ratio of 4.10 and a debt-to-equity ratio of 0.29. Illumina has a 52-week low of $196.78 and a 52-week high of $380.76. The firm has a market capitalization of $53.84 billion, a P/E ratio of 56.71, a PEG ratio of 5.43 and a beta of 0.98. The firm has a 50-day simple moving average of $349.26 and a 200-day simple moving average of $310.73.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.64 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.39. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The company had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $857.92 million. During the same quarter last year, the company posted $1.60 EPS. The firm’s revenue was up 1.5% compared to the same quarter last year. On average, sell-side analysts expect that Illumina will post 6.13 earnings per share for the current fiscal year.

In other Illumina news, SVP Aimee L. Hoyt sold 191 shares of Illumina stock in a transaction on Monday, June 8th. The shares were sold at an average price of $350.94, for a total value of $67,029.54. Following the transaction, the senior vice president now directly owns 3,498 shares in the company, valued at $1,227,588.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 121 shares of Illumina stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $265.92, for a total transaction of $32,176.32. Following the completion of the transaction, the senior vice president now owns 9,962 shares in the company, valued at $2,649,095.04. The disclosure for this sale can be found here. Insiders have sold a total of 37,128 shares of company stock worth $11,980,537 over the last quarter. 0.38% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. Tarbox Family Office Inc. boosted its holdings in shares of Illumina by 5.0% in the first quarter. Tarbox Family Office Inc. now owns 696 shares of the life sciences company’s stock valued at $190,000 after acquiring an additional 33 shares in the last quarter. ACG Wealth boosted its holdings in shares of Illumina by 0.3% in the fourth quarter. ACG Wealth now owns 12,154 shares of the life sciences company’s stock valued at $4,032,000 after acquiring an additional 39 shares in the last quarter. Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of Illumina by 6.7% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 620 shares of the life sciences company’s stock valued at $169,000 after acquiring an additional 39 shares in the last quarter. Farr Miller & Washington LLC DC boosted its holdings in shares of Illumina by 0.8% in the first quarter. Farr Miller & Washington LLC DC now owns 4,671 shares of the life sciences company’s stock valued at $1,276,000 after acquiring an additional 39 shares in the last quarter. Finally, Checchi Capital Advisers LLC boosted its holdings in shares of Illumina by 3.4% in the first quarter. Checchi Capital Advisers LLC now owns 1,222 shares of the life sciences company’s stock valued at $334,000 after acquiring an additional 40 shares in the last quarter. 89.88% of the stock is currently owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: Does a trade war provide a risk to the global economy?

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.